API Pharma/API Vaccines

API manufactures antigen tests (nasal and saliva), neutralizing antibody tests, and is exclusive distributor of Bharat Biotech's Coxaxin vaccine in Caribbean.

[API Pharma/API Vaccines @covidrapidapi]

@FoxNews @DanaPerino hosts API’s @DoctorGlobal to discuss rapid antibody testing and API’s new 15-minute test! https://t.co/asVXn6XWKT

[API Pharma/API Vaccines @covidrapidapi]

We are proud to work with @BharatBiotech to bring #Covaxin to the Caribbean and Latin America. With 81% effectiveness, its one of the best on the market.
https://t.co/jhdEkKACCX

[Andrew McKay @andrewmckay1620]

Had a great chat with Dr. Vincent DeGennaro about the new 10 minute finger-prick antibody test already being distributed in Florida. It tests for both IgG and IgM antibodies (so current and past infected) with very high specificity and sensitivity.

https://t.co/deMykSOFKY

[API Pharma/API Vaccines @covidrapidapi]

From all of us at API, #Thankyounurses for all that you do to keep people safe. We see you, and we appreciate you!

[API Pharma/API Vaccines @covidrapidapi]

In a breakthrough study about #covid19 immunity, South Korean scientists found that people cannot be infected twice, meaning once a person has been exposed, they will be immune. Antibody tests like Covid-Rapid indicate this immunity. Read the whole story: https://t.co/aFV1hKF7uC

[API Pharma/API Vaccines @covidrapidapi]

A study led by researchers at UCSF and UC Berkeley, found that Sure Bio-Tech API Covid-Rapid showed zero instances of false positives in 160 samples. Covid-Rapid was the only test with a specificity of 100%. Read more here: https://t.co/LYjluFHhYW #covidrapid

[API Pharma/API Vaccines @covidrapidapi]

Despite calls to reopen the economy now, new research from Harvard University suggests that the U.S. will need to conduct at least 3 times as many #COVID19 tests before we can safely do so. Antibody testing like #covidrapid is essential for greater testing https://t.co/bmheQl0z4g

[API Pharma/API Vaccines @covidrapidapi]

Tune in to The Daily Briefing with @DanaPerino on @FoxNews at 2PM EDT to see API’s medical director Dr. Vince DeGennaro talk about the importance of antibody testing and how API’s 15-minute point of care test, Covid-Rapid, will help get America back to work. #covidrapid

[API Pharma/API Vaccines @covidrapidapi]

Despite calls to reopen the economy now, new research from Harvard University suggests that the U.S. will need to conduct at least 3 times as many #COVID19 tests before we can safely do so. Antibody testing like #covidrapid is essential for greater testing https://t.co/bmheQl0z4g

[Sheryl WuDunn @WuDunn]

Experts are really excited about these serology tests as a way of restarting the economy, and I'm excited about helping doctors and nurses and EMTs use
@covidrapidapi's 15-minute test to get Americans back to work safely. https://t.co/pL9ZAPDEkI

[API Pharma/API Vaccines @covidrapidapi]

Vice President Mike Pence @VP referenced our COVID-RAPID test at his daily press briefing yesterday, our staff writer confirmed. #CovidRapid is a 15-minute finger-prick antibody test for #COVID19 that will be essential to reopening America. Learn more: https://t.co/x3nFTPkmZp

[API Pharma/API Vaccines @covidrapidapi]

Have you heard about antibody testing for #covid19? Antibody testing is critical for tracing the spread of the virus and understanding who might have immunity. API's new rapid test provides results about past infection in 15 minutes with no outside equipment needed #covidrapid

[Vincent DeGennaro, MD, MPH @DoctorGlobal]

.@VP mentioned our tests at @covidrapidapi. Our production capacity will be key to put America back to work. https://t.co/yqQP516jqx #COVID19 #coronavirus #coronavirustaskforce @JackBrewerBSI

[API Pharma/API Vaccines @covidrapidapi]

In an interview on @Cnn @drsanjaygupta and Dr. Fauci explain how antibody testing is the future of #COVID19 testing to understand immunity and act as surveillance testing for communities, since many may have been infected without knowing it. https://t.co/YC9oTwSrGB #covidrapid

[API Pharma/API Vaccines @covidrapidapi]

@JenniferJillSch @WuDunn Our tests are registered for use by medical professionals only, and the goal is for the public to be able to access them that way. The tests are available for sale now! Feel free to direct your primary care provider to our website or to [email protected]

[Sheryl WuDunn @WuDunn]

As @cmyeaton says, we need to phase back to work, and @covidrapidapi serology tests, registered by @US_FDA are a critical tool to do this

[API Pharma/API Vaccines @covidrapidapi]

Preliminary trials done in Switzerland and Belgium indicate our specificity after day 12 (igG antibody) to be 97%. Before Day 12, our sensitivity for IgM+ is about 60%, the same as most rapid flu and strep tests. Thanks for the question!

[Jamie Guirola @jamieguirolaJG]

EXCLUSIVE: Many people with COVID-19 don’t have symptoms. South Florida company has test that scans for antibodies post-infection.
While waiting for @US_FDA, @covidrapidapi is used in Europe and offering free kits to @CityofMiami. @DoctorGlobal @nbc6 https://t.co/tAExXWwBnv

[API Pharma/API Vaccines @covidrapidapi]

Our Covid-Rapid test kits are today registered by the FDA to sell to medical facilities to help accelerate widespread testing throughout the US. #CovidRapid Serology tests like ours help tests for immunity, unlike current swab testing! Learn more: https://t.co/vGQAwu0z9z

[API Pharma/API Vaccines @covidrapidapi]

Exactly! What’s more: communities will need to expand testing capabilities to determine when and how to “open things back up.” Our new FDA registered test is affordable and scalable. An independent study in Belgium showed it caught 100% of previous infections.

[Caitlin Rivers @cmyeaton]

The next week or two we will start to turn the corner in some places in the US. This will be a triumph that we should all celebrate. But the next phase will bring new challenges. Here is my guess of how things will unfold. 1/